Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about XNCR MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will present preclinical data comparing activity of XmAb®7195 to omalizumab in reducing IgE, a protein responsible for triggering disease activity in asthma and other allergic...
↧